MX2020001337A - Formulaciones que comprenden un acido nucleico en una alta concentracion. - Google Patents
Formulaciones que comprenden un acido nucleico en una alta concentracion.Info
- Publication number
- MX2020001337A MX2020001337A MX2020001337A MX2020001337A MX2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- nucleic acid
- formulations
- high concentration
- viscosity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Las composiciones de ácido nucleico de baja viscosidad y alta concentración que pueden administrarse mediante múltiples vías parenterales podrían permitir una dosificación menos frecuente que los productos de ácido nucleico que se encuentran presentes en la actualidad en el mercado. En particular, las formulaciones de desfibrotides de baja viscosidad para la administración subcutánea, intramuscular e intraperitoneal son más convenientes para el paciente y/o se administran fuera del entorno hospitalario. Las formulaciones de la invención pueden utilizarse en el tratamiento de numerosas afecciones lo que incluye, por ejemplo, el tratamiento de arteriopatías periféricas, el tratamiento de insuficiencia renal aguda, el tratamiento de isquemia miocárdica aguda y el tratamiento y prevención del síndrome de obstrucción sinusoidal o VOD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762540657P | 2017-08-03 | 2017-08-03 | |
PCT/US2018/045152 WO2019028340A1 (en) | 2017-08-03 | 2018-08-03 | FORMULATIONS COMPRISING A HIGH CONCENTRATION NUCLEIC ACID |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001337A true MX2020001337A (es) | 2020-09-09 |
Family
ID=63364168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001337A MX2020001337A (es) | 2017-08-03 | 2018-08-03 | Formulaciones que comprenden un acido nucleico en una alta concentracion. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20200261489A1 (es) |
EP (1) | EP3661484A1 (es) |
JP (1) | JP2020530004A (es) |
KR (1) | KR20200121780A (es) |
CN (1) | CN111132663A (es) |
AR (1) | AR112403A1 (es) |
AU (1) | AU2018309068A1 (es) |
BR (1) | BR112020002289A2 (es) |
CA (1) | CA3071544A1 (es) |
CO (1) | CO2020001873A2 (es) |
IL (1) | IL272405A (es) |
MX (1) | MX2020001337A (es) |
SG (1) | SG11202000952PA (es) |
TW (1) | TW201909904A (es) |
WO (1) | WO2019028340A1 (es) |
ZA (1) | ZA202000676B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190112197A (ko) | 2012-06-22 | 2019-10-02 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2019213053A1 (en) | 2018-04-30 | 2019-11-07 | Gentium S.R.L. | Methods for treating patients having sinusoidal obstruction syndrome |
US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物 |
EP4110287A1 (en) | 2020-02-28 | 2023-01-04 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
EP4135717A1 (en) | 2020-04-17 | 2023-02-22 | Jazz Pharmaceuticals Ireland Limited | Defibrotide treatment for the prevention of organ rejection and injury |
KR20220151414A (ko) * | 2021-05-06 | 2022-11-15 | 연세대학교 산학협력단 | 허혈성 뇌질환 예방 또는 치료용 약학적 조성물 |
WO2022234101A1 (en) | 2021-05-06 | 2022-11-10 | Jazz Pharmaceuticals Ireland Limited | Defibrotide for the treatment and prevention of acute respiratory distress syndrome |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1043823B (it) | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
DE2154279A1 (de) | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
US3899481A (en) | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
IT1170214B (it) | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
IT1206341B (it) | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
US4694134A (en) | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
US4693134A (en) | 1985-06-20 | 1987-09-15 | Excelermatic Inc. | High-powered vehicle drive train |
IT1190313B (it) | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
US5223609A (en) | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
IT1223322B (it) | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
IT1231509B (it) | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
US6699985B2 (en) | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
US5977083A (en) | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
IT1252174B (it) | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
ES2251134T3 (es) | 1999-06-08 | 2006-04-16 | Gentium S.P.A. | Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos. |
US8771663B2 (en) | 2000-04-18 | 2014-07-08 | Gentium Spa | Formulation having mobilising activity |
EP1325962A1 (en) | 2001-12-17 | 2003-07-09 | Gentium S.p.A. | A method for determining the biological activity of defibrotide |
ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
WO2005089503A2 (en) * | 2004-03-19 | 2005-09-29 | Progenics Pharmaceuticals, Inc. | Cd4-igg2 formulations |
KR20070120953A (ko) | 2005-03-03 | 2007-12-26 | 젠티엄 에스피에이 | 항암활성을 갖는 제제 |
EP1872787A1 (en) | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
EP2103689A1 (en) | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
CN101301306A (zh) * | 2008-06-30 | 2008-11-12 | 广东天普生化医药股份有限公司 | Dft在制备治疗和预防休克药物中的应用 |
CN101301308A (zh) * | 2008-06-30 | 2008-11-12 | 广东天普生化医药股份有限公司 | Dft在制备治疗和预防弥散性血管内凝血药物中的应用 |
CN101759767A (zh) | 2008-10-23 | 2010-06-30 | 湖州来色生物基因工程有限公司 | 一种双甘氨肽的合成方法 |
CN102946861B (zh) * | 2010-03-01 | 2016-01-20 | 西托戴恩有限公司 | 浓缩蛋白制剂及其用途 |
DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
KR20190112197A (ko) | 2012-06-22 | 2019-10-02 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
US20160074515A1 (en) * | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
-
2018
- 2018-08-03 EP EP18759469.2A patent/EP3661484A1/en active Pending
- 2018-08-03 AR ARP180102225 patent/AR112403A1/es unknown
- 2018-08-03 WO PCT/US2018/045152 patent/WO2019028340A1/en unknown
- 2018-08-03 JP JP2020506213A patent/JP2020530004A/ja active Pending
- 2018-08-03 TW TW107127108A patent/TW201909904A/zh unknown
- 2018-08-03 SG SG11202000952PA patent/SG11202000952PA/en unknown
- 2018-08-03 CA CA3071544A patent/CA3071544A1/en not_active Abandoned
- 2018-08-03 BR BR112020002289-6A patent/BR112020002289A2/pt not_active Application Discontinuation
- 2018-08-03 MX MX2020001337A patent/MX2020001337A/es unknown
- 2018-08-03 KR KR1020207006232A patent/KR20200121780A/ko unknown
- 2018-08-03 CN CN201880061131.7A patent/CN111132663A/zh active Pending
- 2018-08-03 AU AU2018309068A patent/AU2018309068A1/en not_active Abandoned
- 2018-08-20 US US16/105,319 patent/US20200261489A1/en not_active Abandoned
-
2020
- 2020-01-31 ZA ZA2020/00676A patent/ZA202000676B/en unknown
- 2020-02-02 IL IL272405A patent/IL272405A/en unknown
- 2020-02-20 CO CONC2020/0001873A patent/CO2020001873A2/es unknown
-
2021
- 2021-07-16 US US17/377,972 patent/US20210338707A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR112403A1 (es) | 2019-10-23 |
US20210338707A1 (en) | 2021-11-04 |
SG11202000952PA (en) | 2020-02-27 |
AU2018309068A8 (en) | 2020-02-27 |
US20200261489A1 (en) | 2020-08-20 |
EP3661484A1 (en) | 2020-06-10 |
CN111132663A (zh) | 2020-05-08 |
CO2020001873A2 (es) | 2020-04-13 |
AU2018309068A1 (en) | 2020-02-20 |
JP2020530004A (ja) | 2020-10-15 |
BR112020002289A2 (pt) | 2020-07-28 |
WO2019028340A9 (en) | 2019-08-08 |
KR20200121780A (ko) | 2020-10-26 |
WO2019028340A1 (en) | 2019-02-07 |
TW201909904A (zh) | 2019-03-16 |
IL272405A (en) | 2020-03-31 |
ZA202000676B (en) | 2021-01-27 |
CA3071544A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020001337A (es) | Formulaciones que comprenden un acido nucleico en una alta concentracion. | |
NZ734233A (en) | Pharmaceutical compositions comprising meloxicam | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
MA43574A (fr) | Compositions ayant des amplificateurs de perméation pour l'administration de médicaments | |
WO2015138357A3 (en) | Compositions useful in treatment of otc deficency | |
TN2018000056A1 (en) | Rapid-acting insulin compositions. | |
MX2018004834A (es) | Metodos para tratar dolor usando dimeros de acetominofeno farmaceuticamente activos enlazados a traves de grupos hidroxilo fenolicos. | |
PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
WO2015148580A3 (en) | Una oligomers having reduced off-target effects in gene silencing | |
PH12020500076A1 (en) | Long-acting formulations | |
CY1118074T1 (el) | Ανθελονοσιακοι παραγοντες | |
TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
NZ723139A (en) | Fgf-18 compound dosing regimen | |
EA201991265A1 (ru) | Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат | |
MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
MX368735B (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. | |
MD4763C1 (ro) | Compoziţie farmaceutică | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
MX2022013237A (es) | Maltodextrinas entrelazadas para el suministro oral de activos biologicos. | |
WO2014104989A8 (en) | Pharmaceutical compositions comprising aripiprazole | |
WO2019098691A3 (ko) | 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법 | |
MD20170071A2 (ro) | Compoziţii injectabile de paracetamol | |
MX2018003564A (es) | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer. | |
MX2017016978A (es) | Composicion farmaceutica de heparinas de bajo peso molecular. | |
MX2021000312A (es) | Composicion farmaceutica que contiene un peptido. |